1. The pseudorabies virus R2 non-neuroinvasive vaccine: A proof-of-concept study in pigs
- Author
-
Patricia J. Sollars, Bruce W. Brodersen, Gregory A. Smith, and Gary E. Pickard
- Subjects
Swine ,viruses ,030231 tropical medicine ,Pseudorabies ,Virulence ,Context (language use) ,Antibodies, Viral ,Article ,Virus ,03 medical and health sciences ,0302 clinical medicine ,Pseudorabies Vaccines ,medicine ,Animals ,030212 general & internal medicine ,Swine Diseases ,Vaccines ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Public Health, Environmental and Occupational Health ,Viral Vaccines ,biology.organism_classification ,Herpesvirus 1, Suid ,Virology ,Vaccination ,Infectious Diseases ,medicine.anatomical_structure ,Peripheral nervous system ,Molecular Medicine ,Nasal administration ,business - Abstract
Neurotropic alpha-herpesviruses that infect mammals establish life-long latent infections in the peripheral nervous system after initial infection of exposed mucosal tissues. The neuroinvasive properties can lead to severe complications both with clinical and veterinary alpha-herpesviruses, and vaccines are often unavailable or provide limited protection. Here we assess the properties and efficacy of an R2 vaccine derived from the alpha-herpesvirus, pseudorabies virus (PRV), in pigs. We demonstrate that the PRV R2 vaccine does not invade the porcine peripheral nervous system within the limits of detection. Furthermore, after a single intranasal vaccination, R2 conferred protection to pigs subsequently challenged with a virulent PRV field strain (NIA-3). These findings support that the R2 vaccine design is non-neuroinvasive and is an effective vaccine in the context of a natural host.
- Published
- 2020
- Full Text
- View/download PDF